Live Trading News
Shayne Heffernan

China downgrades COVID-19

By Shayne Heffernan4 min read

China put its downgraded COVID-19 measures into force on Sunday as the nation began to resume normal life after three years of strict pandemic management.

The nation reopened its border ports for cargo transportation as well as inbound and outbound visitors. It also resumed services for Chinese citizens to apply for passports and visas for business and recreation.

Quarantine and on-site COVID-19 tests for the inbound visitors were scrapped, as well as preventative disinfection on imported goods and sampling inspection on cold-chain food.

The country will no longer enforce quarantine measures or mass COVID-19 tests. Practices of identifying close contacts or designating high- and low-risk areas have also discontinued.

Policy changes

China downgraded management of COVID-19 from Class A to Class B and removed it from quarantinable infectious disease management following an array of recent policy shifts regarding the virus, as the nation hit a full vaccination rate of over 90 percent and the COVID-19 virus exhibited less severity.

During the pandemic, COVID-19 was classified as a Class-B infectious disease but was subject to the preventive and control measures for a Class-A infectious disease in China, coming with stringent policies such as quarantine and frequent epidemiological surveys.

China has categorized 40 notifiable infectious diseases in three classes (Class A, Class B and Class C). Plague and cholera are listed as Class A infectious diseases. SARS, AIDS and tuberculosis are among the Class B infectious diseases. Class C infectious diseases include influenza and mumps.

An infectious disease is categorized based on a comprehensive assessment of multiple factors including pathogen characteristics, symptoms, how far and fast it can spread, how much it harms health, its social and economic influence, as well as group immunity and health system capability, according to Liang Wannian, head of the COVID-19 response expert panel under China's National Health Commission (NHC).

"At the outbreak of the pandemic, we categorized COVID-19 as a Class B disease but applied Class A management because of its rapid spread," said Liang, adding that they didn't know much about the disease at the beginning, and such management was needed to protect people.

Liang explained some key conditions have changed recently including the less deadly virus mutation, high vaccination rate and the country's growing epidemic response support, all of which built a great foundation to make new adjustments.

"We are ready to downgrade it to Class B management to respond to the infections in a more precise, scientific manner," said Liang.

The expert also stressed that the downgraded management doesn't mean the country has no control on or has stopped all preventative measures against the virus.

"It means we are stepping up our health services and epidemic response capability," said Liang.

China renamed the Chinese term for COVID-19 in December from "novel coronavirus pneumonia" to "novel coronavirus infection" to more accurately describe the disease.

Stepped-up COVID-19 response

The NHC released its 10th edition of the guidelines for COVID-19 infection prevention and control on Saturday, emphasizing the importance of boosting vaccination among high risk groups such as the elderly.

It reinforced monitoring and early warning capabilities, including regular monitoring on virus mutation, unknown pneumonia, urban wastewater, hospitals and extra steps in emergency such as monitoring among key groups.

Communities will no longer go through mass COVID-19 tests, which will be provided for those who require them.

"For now, medical treatment for severe cases is our priority," said Liang. He said further boosting vaccination, virus monitoring and suburb healthcare capability are of great importance.

"For any contagious disease like this, it's not enough to only depend on the government," Liang said, "it depends on the synergy coming from the government, society, all the organizations and each one of us."

Keep reading
phonons

Phonons: The Particles of Vibration, From Constraint to Control

A phonon is one quantum of lattice vibration. Phonons carry the heat that limits AI chips, make the radio filters in phones work and are the moving part of trapped-ion quantum computers. In superconducting quantum chips they are the threat: a particle hit spreads through the chip as phonons and causes error bursts. Four results between 12 October and 20 November 2026 measured, steered and modelled them with new precision.

Shayne Heffernan25 min
$ANT

AI Sell-Off Is Noise and Demand Is Rising

In my view the AI sell-off is noise. Anthropic priced its IPO at $83 on 18 November 2026 and closed its first day at $97.17. NVIDIA reported a $115.8 billion quarter and guided to $130 billion, yet closed at $125.53 on 20 November 2026, 47.5% below its record. Ramp puts paid business adoption of AI at 56.8%, up 1 point. KXCO's AI ontology ranks Oracle, Alibaba and NVIDIA as the three profitable names with the most upside to the analysts' targets.

Shayne Heffernan15 min
$INO

KXCO Three for Three on FDA Decisions

The FDA has ruled on three drugs on KXCO's FDA board since we set our model books in October 2026, and all three are wins for the books. They held INO-3107, and the FDA approved it on 30 October. They held neither ivonescimab nor deramiocel, and the FDA refused both. Per the books' public ledger and Yahoo Finance closes, from 14 October to 20 November 2026, Book 1 rose 0.9% and Book 2 rose 2.1%, while the S&P 500 fell 10.5%, the Nasdaq 15.3%, the Dow 6.7% and XBI 4.5%.

Shayne Heffernan14 min
$INO

KXCO's FDA Ontology Is Two for Two on FDA Decisions

The FDA has decided two filings on KXCO's FDA board since the board began ranking them, and on my scorecard the board got both right. It ranked Inovio's INO-3107 first and the FDA approved it on 30 October; Inovio moved +149.1% net of the sector. It gave Summit's ivonescimab no call, and Summit announced the FDA's refusal on 15 November; Summit fell 16.5%. KXCO's record held the FDA's survival warning before the refusal was announced.

Shayne Heffernan12 min
Read Live Trading News on Telegram

Every story, signed and delivered.

Subscribe to the kxco channel and get the headline, the AI-written key takeaways, and the chain-anchor link the moment we publish. Audio versions and per-ticker subscriptions arrive in the next iteration.

Open @KnightsbridgeInsightsNo email required.